Please login to the form below

Not currently logged in
Email:
Password:

MYSTIC trial

This page shows the latest MYSTIC trial news and features for those working in and with pharma, biotech and healthcare.

Innate Pharma and AstraZeneca take monalizumab into phase 3

Innate Pharma and AstraZeneca take monalizumab into phase 3

The trial is set to begin in 2020, depending on regulatory and compliance approvals. ... However, the drug also failed to hit the first of two primary endpoints in the MYSTIC trial of Imfinzi plus AZ’s experimental CTLA4 inhibitor tremelimumab in

Latest news

  • AZ’s Imfinzi combo bombs again in non-small cell lung cancer AZ’s Imfinzi combo bombs again in non-small cell lung cancer

    The same combination failed to move the needle in the MYSTIC trial, but signs of an improvement in a subgroup of patients with a particular cancer biomarker – high tumour mutational burden ... Meanwhile, the PEARL trial is pitting Imfinzi against

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    During the MYSTIC trial, Imfinzi failed to hit the mark on progression-free survival and overall survival endpoints, but AstraZeneca said it would try the drug’s luck as a monotherapy ... However, AZ has confirmed that Imfinzi did demonstrate clinical

  • AZ still sees route to approval for Imfinzi in MYSTIC trial AZ still sees route to approval for Imfinzi in MYSTIC trial

    expand and tweak the protocol of its ongoing NEPTUNE trial of Imfinzi with tremelimumab in first-line NSCLC that is due to generate results early next year. ... month and it is hard to explain why the duo performed worse than Imfinzi on its own in MYSTIC.

  • Is AstraZeneca looking for its next CEO? Is AstraZeneca looking for its next CEO?

    The rumour has surfaced just days after the company confirmed that its immuno-oncology (IO) combination trial MYSTIC (twinning Imfinzi with CTLA4 candidate tremelimumab) failed to outperform chemo in overall survival

  • AZ’s MYSTIC survival data is in – and it’s a bust AZ’s MYSTIC survival data is in – and it’s a bust

    Imfinzi failed to achieve OS improvement. AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    The NELSON trial, which looked at screening in Europe, was presented at the recent World Conference on Lung Cancer. ... However, recent overall survival results from the MYSTIC trial, which studied Imfinzi with CTLA4 inhibitor tremelimumab, have just

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Open-minded culture. Like the new HQ’s construction, there have been setbacks – such as the setback to its Imfinzi tremelimumab immunotherapy combination in the MYSTIC lung cancer trial last year –

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics